-

OCUGEN INVESTIGATION CONTINUED By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Ocugen, Inc. - OCGN

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF continues to investigate Ocugen, Inc. (NasdaqCM: OCGN).

On June 10, 2021, the Company disclosed that it would pursue a “biologics license application” with the U.S. Food and Drug Administration for its COVID-19 vaccine candidate/product rather than the Emergency Use Authorization process that it had previously stated it would utilize.

The Company has been sued in a securities class action lawsuit for failing to disclose material information, violating federal securities laws, which is ongoing.

KSF’s investigation is focusing on whether Ocugen’s officers and/or directors breached their fiduciary duties to Ocugen’s shareholders or otherwise violated state or federal laws.

If you have information that would assist KSF in its investigation, or have been a long-term holder of Ocugen shares and would like to discuss your legal rights, you may, without obligation or cost to you, call toll-free at 1-877-515-1850 or email KSF Managing Partner Lewis Kahn (lewis.kahn@ksfcounsel.com), or visit https://www.ksfcounsel.com/cases/nasdaqcm-ocgn/ to learn more.

About Kahn Swick & Foti, LLC

KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation’s premier boutique securities litigation law firms. KSF serves a variety of clients – including public institutional investors, hedge funds, money managers and retail investors – in seeking to recover investment losses due to corporate fraud and malfeasance by publicly traded companies. KSF has offices in New York, California, Louisiana and New Jersey.

To learn more about KSF, you may visit www.ksfcounsel.com.

Contacts

Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
lewis.kahn@ksfcounsel.com
1-877-515-1850

Kahn Swick & Foti, LLC

NASDAQ:OCGN

Release Versions

Contacts

Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
lewis.kahn@ksfcounsel.com
1-877-515-1850

More News From Kahn Swick & Foti, LLC

Crinetics Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Crinetics Pharmaceuticals, Inc. - CRNX

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Crinetics Pharmaceuticals, Inc. (NasdaqGS: CRNX) to Vertex Pharmaceuticals Incorporated (NasdaqGS: VRTX). Under the terms of the proposed transaction, shareholders of Crinetics will receive $85.00 in cash for each share of Crinetics that they own. KSF is seeking to determine whether this consideratio...

Element Solutions Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Element Solutions Inc - ESI

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Element Solutions Inc (NYSE: ESI) to Solstice Advanced Materials, Inc. (NasdaqGS: SOLS). Under the terms of the proposed transaction, shareholders of Element will receive $10.00 in cash and 0.500 shares of Solstice common stock for each share of Element that they own. Upon closing of the Propose...

Kyndryl Holdings Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Kyndryl Holdings, Inc. - KD

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Kyndryl Holdings, Inc. (“Kyndryl” or the “Company”) (NYSE: KD).On February 9, 2026, the Company disclosed that it would be unable to timely file its Form 10-Q Report for the quarter ended December 31, 2025 and that “the Company anticipates reporting material weaknesses in...
Back to Newsroom